Sciwind Biosciences Entered into a Research Collaboration with SynerK to Develop Novel siRNA Therapies for Liver and Metabolic Diseases
Shots:
- The collaboration will combine Sciwind's expertise in disease biology and clinical development capabilities with SynerK's conjugate-based siRNA delivery technology and expertise to develop novel siRNA therapies against new therapeutic targets for the treatment of liver and metabolic diseases
- The delivery technology platform demonstrated a good safety profile both in vitro and in vivo, along with a high delivery efficiency to the targeted human cells
- SynerK plans to work with Sciwind to investigate new opportunities for siRNA therapeutics discovery to assist patients with unmet medical needs by using siRNA delivery technology
Ref: PRNewswire | Image: Sciwind Biosciences
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
